Showing 761 - 780 results of 2,530 for search '"vaccines"', query time: 0.07s Refine Results
  1. 761
  2. 762
  3. 763
  4. 764
  5. 765
  6. 766
  7. 767
  8. 768
  9. 769
  10. 770
  11. 771
  12. 772
  13. 773
  14. 774

    How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines by R. Gasparini, D. Panatto, N. L. Bragazzi, P. L. Lai, A. Bechini, M. Levi, P. Durando, D. Amicizia

    Published 2015-01-01
    “…Nowadays different licensed meningococcal vaccines are available and used: conjugate meningococcal C vaccines, tetravalent conjugate vaccines, an affordable conjugate vaccine against the N. menigitidis serogroup A, and universal vaccines based on multiple antigens each one with a different and peculiar function against meningococcal group B strains.…”
    Get full text
    Article
  15. 775

    Haemophilus parasuis Subunit Vaccines Based on Native Proteins with Affinity to Porcine Transferrin Prevent the Expression of Proinflammatory Chemokines and Cytokines in Pigs by R. Frandoloso, S. Martínez-Martínez, E. F. Rodríguez-Ferri, S. Yubero, D. Rodríguez-Lázaro, M. Hernández, C. B. Gutiérrez-Martín

    Published 2013-01-01
    “…The expression of chemokines (CCL-2 and CXCL-8) and cytokines (IL-1α, IL-1β, IL-6, TNF-α, and IL-10) was evaluated by RT-qPCR in colostrum-deprived pigs vaccinated and challenged with Haemophilus parasuis serovar 5. …”
    Get full text
    Article
  16. 776
  17. 777

    Evaluation of Immune Characteristics and Factors Associated with Immune Response following Hepatitis B Vaccination among Ghanaian Adolescents by Samuel Asamoah Sakyi, Joseph Badu Gyapong, Ebenezer Krampah Aidoo, Alfred Effah, Simon Koffie, Oscar Simon Olympio Mensah, Isaac Arddey, Godwin Boakye, Stephen Opoku, Benjamin Amoani, Robert Amadu Ngala

    Published 2024-01-01
    “…WHO recommends HBV-negative babies in high-prevalence (8%) countries receive anti-HBV vaccination. Ghana initiated mass immunization in 2002, but concerns remain about vaccine effectiveness and long-term protection. …”
    Get full text
    Article
  18. 778

    Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination by Francesca Dapporto, Serena Marchi, Margherita Leonardi, Pietro Piu, Piero Lovreglio, Nicola Decaro, Nicola Buonvino, Angela Stufano, Eleonora Lorusso, Emilio Bombardieri, Antonella Ruello, Simonetta Viviani, Eleonora Molesti, Claudia Maria Trombetta, Alessandro Manenti, Emanuele Montomoli

    Published 2022-01-01
    “…Samples were collected from 42 SARS-CoV-2 infected patients during the first pandemic wave, 50 subjects who received 2 doses of mRNA vaccine before the Omicron wave, 44 subjects who received 3 doses of mRNA vaccine, and 35 subjects who received heterologous vaccination (2 doses of adenovirus-based vaccine plus mRNA vaccine) during the Omicron wave. …”
    Get full text
    Article
  19. 779
  20. 780

    N-Terminal Plasmodium vivax Merozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine by Fernanda G. Versiani, Maria E. Almeida, Luis A. Mariuba, Patricia P. Orlandi, Paulo A. Nogueira

    Published 2013-01-01
    “…The lack of in vitro cultures for P. vivax represents a major delay in developing a functional malaria vaccine. One of the major candidates to antimalarial vaccine is the merozoite surface protein-1 (MSP1), which is expressed abundantly on the merozoite surface and capable of activating the host protective immunity. …”
    Get full text
    Article